All lobbying filings

DLA Piper LLP (US)

DLA Piper LLP (US) filed a Q4 report for Currax Pharmaceuticals LLC on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Currax Pharmaceuticals LLC · Specialty pharmaceutical business

As filed: DLA PIPER LLP (US) for CURRAX PHARMACEUTICALS LLC.

All filings by DLA Piper LLP (US) · Everything Currax Pharmaceuticals LLC has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Tennessee

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.

Bills named in this filing 2

H.R. 4231
Treat and Reduce Obesity Act of 2025
S. 1973
Treat and Reduce Obesity Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.